Abstract P5-04-01: PARP inhibition modulates the infiltration, phenotype and function of tumor-associated macrophages (TAMs) in BRCA-associated breast cancer and can be augmented by harnessing the anti-tumor potential of TAMs
Jennifer L. Guerriero(Brigham and Women's Hospital), Elizabeth A. Mittendorf(Beth Israel Deaconess Medical Center), Evisa Gjini(Brigham and Women's Hospital), Sandro Santagata(Harvard University), Gerburg M. Wulf(Beth Israel Deaconess Medical Center), Sholin Mei(Harvard University), Constantia Pantelidou(Harvard University), Olmo Sonzogni(Beth Israel Deaconess Medical Center), Matthew J. Berberich(Harvard University), Christina Hartl(Io Therapeutics (United States)), Geoffrey I. Shapiro(Brigham and Women's Hospital), Anita K. Mehta(Dana-Farber Cancer Institute), Brett Gross(Dana-Farber Cancer Institute), Nadine Tung(Beth Israel Deaconess Medical Center), Jia‐Ren Lin(Harvard University), Sarah A. Boswell(Harvard University), Scott J. Rodig(Brigham and Women's Hospital), Mateus de Oliveira Taveira(Memorial Sloan Kettering Cancer Center), Peter K. Sorger(Harvard University Press), Deborah Dillon(Harvard University), Nathan Johnson(Harvard University), Mikel Lipschitz(Brigham and Women's Hospital), William M. Oldham(Brigham and Women's Hospital), Marian Kalocsay(The University of Texas MD Anderson Cancer Center), Shawn F. Johnson(Harvard University), Jessica A. Castrillon(Dana-Farber Cancer Institute), Emily Cheney(Dana-Farber Cancer Institute), Dan Wang(Breast Cancer Now), Judy E. Garber(Dana-Farber Cancer Institute)
Cited by 0